This site uses cookies to improve your browsing experience. By using this site, you agree to their use. Cookie Policy

InOncology.com

WCLC, YOKOHAMA, 15 - 18 OCTOBER 2017 - 1200.32/34/123

Analysis of long-term response to first-line afatinib in the LUX-Lung 3, 6 and 7 trials in advanced EGFRm+ NSCLC

Martin Schuler, James Chih-Hsin Yang, Lecia V. Sequist, Yi-Long Wu, Caicun Zhou, Sarayut L Geater, Tony Mok, Eng-Huat Tan, Cheng-Ping Hu, Nobuyuki Yamamoto, Jifeng Feng, Kenneth O’Byrne, Shun Lu, Vera Hirsh, Yunchao Huang, Stuart Ellis, Carl Samuelsen, Angela Märten, Jean Fan, Keunchil Park, Luis Paz-Ares

1200.32_34_123 LL367 LTR - WCLC 2017

Related Materials

Learn more about the science behind this poster in the videos, papers and other materials below.

Afatinib versus gefitinib as first-line treatment of patients with EGFR mutation-positive non-small-cell lung cancer (LUX-Lung 7): a phase 2B, open-label, randomised controlled trial

Park K, et al. Lancet Oncol 2016;17(5):577–89

Afatinib versus cisplatin-based chemotherapy for EGFR mutation-positive lung adenocarcinoma (LUX-Lung 3 and LUX-Lung 6): analysis of overall survival data from two randomised, phase 3 trials

Yang JC, et al. The Lancet Oncology, Volume 16, Issue 2, February 2015, Pages 141-151

Afatinib versus gefitinib in patients with EGFR mutation-positive advanced non-small-cell lung cancer overall survival data from the phase Iib LUX-Lung 7 trial

Paz-Ares L, et al. Annals of Oncology 1-9 2017 doi: 10.1093/annonc/mdw611

Effect of dose adjustment on the safety and efficacy of afatinib for EGFR mutation-positive lung adenocarcinoma: post hoc analyses of the randomized LUX-Lung 3 and 6 trials

Yang, et al. Ann Oncol (2016) 27 (11): 2103-2110. doi: 10.1093/annonc/mdw322

First-line afatinibfor advanced EGFRmutation-positive (EGFRm+) NSCLC: analysis of long-term responders in the LUX-Lung 3, 6 and 7 trialsMartin

Schuler M, et al. ECCO 2017:1 991